Guilherme Andretta, PharmD, MBA

Director, Therapeutic Strategy Clinical Scientist, IQVIA

Articles by Guilherme Andretta, PharmD, MBA

© photon_photo - © photon_photo - stock.adobe.com

As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass preservation, and preparing for expanded safety and demographic requirements that will define the next era of obesity R&D.

Latest Updated Articles